Moexipril in arterial hypertension treatment among postmenopausal women with osteoporosis

• Main Authors: O. D. Ostroumova, E. A. Smolyarchuk, E. G. Shorikova, V. A. Polikarpov, M. P. Rubin, S. V. Paukov
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 1970-01-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: arterial hypertension; women; postmenopause; osteoporosis; densitometry; ace inhibitors
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1567

Aim. To study effectiveness and safety of long-term monotherapy with АСГ inhibitor moexipril, as well as its combination with diuretic hydrochlorthiazide (HCT), in postmenopausal women with arterial hypertension (AH). Material and methods. In total, 38 women with postmenopause duration of 5 years and longer, aged 58-89 years, with untreated or treated ineffectively Stage I-II AH, and postmenopausal femoral osteoporosis, were followed up for 3 three years. Intervention group (n = 19) received moexipril (7,5-15 mg/d), plus CHT (12,5-25 mg/d) if target blood pressure, BP (<140/90 mm Hg), was not achieved. Control group (n = 19) received any antihypertensive agents chosen by the physician, excluding moexipril and thiazide diuretics. Results. By Week 16 of the treatment, the whole intervention group achieved target BP levels, including 52,6% for moexipril monotherapy; target BP levels were maintained for at least 3 years of follow-up. In control group, by Week 16, target BP was achieved in all participants, including 56,2% for monotherapy; nevertheless, 3 years later, target BP was maintained in 12 out of 19 women. By Week 8, moexipril monotherapy in intervention group was associated with significant reduction in systolic and diastolic BP (SBP, DBP) levels in daytime, nighttime and 24 hours. Daytime SBP and DBP variability significantly reduced, morning SBP and DBP surge significantly decreased. Three years later, according to densitometry data, minimal femoral bone density decreased by 4,3% in intervention group, and by 9,9% in control group (p<0,05). Moexipril demonstrated very good (n = 14) and good (n = 5) tolerability Conclusion. Moexipril, as monotherapy and in combination with HCT, is a highly effective and safe agent for long-term AH treatment in postmenopausal women with osteoporosis.